{"id":"paaa","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, PAAA reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.","oneSentence":"PAAA is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:19.200Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT00857675","phase":"PHASE3","title":"A Efficacy and Safety Study of Adefovir Dipivoxil to Treat Chinese Patients With HBeAg+ve Chronic Hepatitis B","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-12","conditions":"Chronic Hepatitis B","enrollment":480}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":92,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PAAA","genericName":"PAAA","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PAAA is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}